Constipation on a GLP-1: The One Side Effect That Doesn't Climb With Your Dose

The number nobody quotes

Almost everything you have read about GLP-1 side effects follows one shape: it is worst right after a dose increase, and it settles as your body adapts. For nausea, that story holds up well. For constipation, the trial data run the other way — and the difference is not small.

Here is Table 1 from Zepbound's prescribing information, the adverse reactions reported at 2% or more and above placebo across its two weight-management trials¹.

Read down the last row. Nausea climbs with dose. Diarrhea climbs. Vomiting nearly doubles from the lowest dose to the highest. Constipation is the only gastrointestinal reaction in the table that goes the other way: highest in the lowest-dose arm, and at 15 mg it is barely more than half what it was at 5 mg.

This is not a quirk of one drug. Ozempic's table shows the same shape — constipation in 1.5% on placebo, 5.0% at 0.5 mg, and 3.1% at the higher 1 mg dose². On Wegovy, constipation affected 24% against 11% on placebo in the main obesity trials, and in the trial testing a 7.2 mg dose it sat at 19% for 2.4 mg and 20% for 7.2 mg — essentially flat where nausea was not³.

What this does not mean

This is the part that matters, and it is where it would be easy to sell you something.

These are comparisons between treatment arms — different groups of people randomized to different doses. They are not the same women followed up a titration ladder. A trial like this cannot tell you that your own constipation will ease as you escalate, and anyone who says the data show that has misread what kind of data it is.

There are ordinary reasons a low-dose arm might report more constipation without the drug being kinder at higher doses. People at higher doses lose more weight and eat differently. Those who found the drug intolerable early may not be represented the same way across arms. Reporting patterns shift once a symptom feels familiar.

So the honest claim is narrow and still useful: across three labels, constipation does not show the dose-climbing pattern that nausea, vomiting and diarrhea all show. Whatever drives it, it is not simply "more drug, more constipation."

Why the usual advice is aimed at the wrong symptom

The standard counsel — expect a flare after each step up, wait it out, it settles — was built on the nausea curve, and for nausea it fits the numbers. Applied to constipation it quietly implies that if you can just get through the next escalation, this resolves itself. The dose-response data give no support to that, and if you are waiting out a symptom that was never going to track your titration schedule, you are waiting instead of treating it.

Constipation is also the GI symptom most likely to be dismissed as trivial by everyone except the person having it. It compounds. It is the one that turns into hemorrhoids, fissures and a week you plan around, and unlike nausea it does not announce itself as a reason to call anyone.

How good is the advice on managing it?

Worth knowing exactly. In 2026 an international panel of physicians, clinical researchers and dietitians published a consensus statement on nutritional and lifestyle care for people on these drugs, built through a modified Delphi process on a scoping review running from January 2021 to June 2025. It produced 52 statements, covering nausea, vomiting, diarrhea and constipation among much else⁴.

Then it says the thing consensus statements usually bury. Those recommendations were drawn primarily from indirect evidence — existing guidelines for nutrition therapy in bariatric medicine, plus clinical experience — and the authors close by stating that direct evidence is urgently required⁴.

That is not a reason to ignore the fiber-and-fluids advice. It is a reason to know its status: it is expert extrapolation from a neighboring field, not a finding from trials in people taking these drugs. If it does not work for you, you have not failed a protocol, because there isn't one.

The wider safety picture sits on firmer ground. A 2025 systematic review in Annals of Internal Medicine pooled 26 randomized controlled trials covering 15,491 participants — 72% of them women — and concluded that the reported safety concerns with these drugs are predominantly gastrointestinal. Participants in those trials were not, however, comparable enough for the reviewers to pool the numbers: heterogeneity prevented meta-analysis, and there were no head-to-head trials at all⁵.

Where this sits on the evidence scale

The dose figures are as solid as this gets — adverse-reaction tables from three prescribing labels, drawn from randomized placebo-controlled trials in tens of thousands of people, and consistent across drugs. That constipation does not follow the dose-climbing pattern is a real finding.

Why it behaves that way is unexplained, and the between-arm limitation means it cannot be turned into a prediction about your own titration. The management advice is the weakest link: 52 consensus statements resting largely on indirect evidence from bariatric nutrition, with the panel itself calling for direct research⁴. Anyone offering you a confident protocol for this is going beyond what has been studied.